Medications for tachycardia
Pro Research Analysisby 
Searched over 200M research papers
Medications for Tachycardia: Overview and Key Drug Classes
Tachycardia, or abnormally fast heart rate, can arise from various causes and requires different medication strategies depending on the specific type and patient population. The main types discussed in recent research include postural orthostatic tachycardia syndrome (POTS), supraventricular tachycardia (SVT) in infants, children, and adults, as well as fetal tachycardia.
Medications for Postural Orthostatic Tachycardia Syndrome (POTS)
Several medications have been studied for POTS, though high-quality evidence is limited. The most frequently used and studied drugs include beta-blockers, ivabradine, and midodrine. Ivabradine and midodrine are associated with the highest rates of symptom improvement, while beta-blockers are most effective at reducing heart rate variability. Fludrocortisone and selective serotonin reuptake inhibitors (SSRIs) have also shown some benefit in individual studies, but overall, there is a lack of standardized treatment protocols and more research is needed to determine the best long-term options for POTS, including cases related to post-acute sequelae of COVID-19 (PASC) 13.
Medications for Supraventricular Tachycardia (SVT) in Infants and Children
Acute and Chronic Management
For infants and children with SVT, a variety of medications are used, but there is no clear consensus or strong evidence favoring one drug over another. In acute settings, commonly used medications include digoxin, procainamide, esmolol, propranolol, and amiodarone. For chronic management, digoxin and propranolol are most frequently chosen, with amiodarone, sotalol, atenolol, and flecainide also used in certain cases. The choice of medication is often influenced by the presence of preexcitation and the physician’s training background 249.
Effectiveness and Safety
Recent large cohort studies and systematic reviews show that propranolol is the most commonly used medication for both acute and maintenance therapy in infants, while digoxin is used less frequently by contemporary pediatric electrophysiologists. There is no significant difference in effectiveness between the main antiarrhythmic drugs for preventing SVT recurrence, and the overall risk of recurrence and adverse events is low. Combination therapy may be required in some cases, especially when monotherapy is insufficient 469.
Medications for Fetal Tachycardia
For fetal tachycardia, especially when associated with hydrops, combination therapy with digoxin and flecainide is superior to digoxin alone. Flecainide monotherapy is also effective. Sotalol and combinations with sotalol do not show significant advantages over digoxin alone. Importantly, there are no significant differences in mortality risk among the different regimens .
Antiarrhythmic Drugs for Stable Tachyarrhythmias
In stable tachycardia cases, antiarrhythmic drugs are chosen based on the underlying mechanism (automaticity or reentry) and patient-specific factors. A broad range of antiarrhythmic drugs is available, and careful diagnosis is essential to select the most appropriate medication and avoid contraindications .
Emerging and Experimental Therapies
New pharmacological approaches for SVT are being explored, targeting not only ion channels but also upstream mechanisms like inflammation and structural remodeling. These advances may lead to more personalized and effective treatments in the future, especially for patients who are not candidates for catheter ablation .
Special Considerations: Medication-Induced Tachycardia
Certain medications, such as antipsychotics, can themselves cause severe tachycardia, particularly in psychiatric inpatients. The risk is higher with second-generation antipsychotics, and clinicians should be aware of this potential side effect when managing patients on these drugs .
Conclusion
A variety of medications are available for the management of tachycardia, with choices depending on the specific type (POTS, SVT, fetal tachycardia), patient age, and clinical context. Beta-blockers, ivabradine, midodrine, digoxin, propranolol, amiodarone, flecainide, and sotalol are among the most commonly used drugs. While some medications show particular promise for certain subtypes, there is a general need for more high-quality, comparative research to guide optimal treatment strategies. Combination therapy may be necessary in some cases, and emerging drugs may offer new options in the future.
Sources and full results
Most relevant research papers on this topic